MSDC 0160 Mitoglitazone; CAY10415|cas:146062-49-9|西域试剂

MSDC 0160 Mitoglitazone; CAY10415,98.55%

产品编号：Bellancom-100550| CAS NO：146062-49-9| 分子式：C₁₉H₁₈N₂O₄S| 分子量：370.42

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100550	￥530.00	杭州北京（现货）
Bellancom-100550	￥1600.00	杭州北京（现货）
Bellancom-100550	￥5000.00	杭州北京（现货）
Bellancom-100550	￥7000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MSDC 0160 Mitoglitazone; CAY10415

产品介绍

MSDC 0160 (Mitoglitazone) 是调节噻唑烷二酮的线粒体靶标 (mTOT) 的胰岛素增敏剂，也是线粒体丙酮酸载体 (MPC) 的调节剂。MSDC 0160 是一种噻唑烷二酮 (TZD)，具有抗糖尿病和神经保护活性作用。MSDC 0160 具有用于阿尔茨海默氏病的潜力。

生物活性

MSDC 0160 (Mitoglitazone) is a mitochondrial target of thiazolidinediones (mTOT)-modulating insulin sensitizer and a modulator of mitochondrial pyruvate carrier (MPC). MSDC 0160 is a thiazolidinedione (TZD) with antidiabetic and neuroprotective activities. MSDC 0160 has the potential for Alzheimer′s disease.

体外研究

MSDC 0160 (Mitoglitazone; 1-50 µM; for 24 hours) significantly decreases phosphorylation of mTOR at 20 and 50 µM.
MSDC 0160 acts as insulin sensitizers without activating PPARγ.
MSDC 0160 (10 μM; pretreatment 1 hour) prevents the MPP⁺ (10 μM)-induced loss of both tyrosine hydroxylase (TH)-immunoreactive differentiated Lund human mesencephalic (LUHMES) cells.
MSDC 0160 (10 or 100 μM) prevents the loss of GFP-fluorescent dopaminergic neurons induced by MPP⁺ (0.75 mM) in nematodes.
MSDC 0160 (10-20 μM) in conbination with IGF-1 prevents the loss of insulin content and maintains insulin secretion.
MSDC 0160 (1-50 μM) treatment maintains human β-cell phenotype.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Human islets
Concentration:	1, 10, 20, 50 µM
Incubation Time:	For 24 hours
Result:	Significantly decreased Phosphorylation of mTOR at 20 and 50 µM.

体内研究
(In Vivo)

MSDC 0160 (Mitoglitazone; 30 mg/kg; oral gavage; daily; for 7 days) improves locomotor behavior, increases survival of nigral dopaminergic neurons, boosts striatal dopamine levels, and reduces neuroinflammation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g
Dosage:	30 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g
Dosage:	30 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ten- to 12-week-old male C57BL/6J mice weighing 24 to 28 g
Dosage:	30 mg/kg
Administration:	Oral gavage; daily; for 7 days
Result:	Improved locomotor behavior, increased survival of nigral dopaminergic neurons, boosted striatal dopamine levels, and reduced neuroinflammation.

性状

Solid

溶解性数据

In Vitro:

DMSO : 33.33 mg/mL (89.98 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.6996 mL	13.4982 mL	26.9964 mL
5 mM	0.5399 mL	2.6996 mL	5.3993 mL
10 mM	0.2700 mL	1.3498 mL	2.6996 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.75 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.75 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (6.75 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (6.75 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。